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We have generated transgenic mice expressing a ki-
nase-deficient type II transforming growth factor-
(TGF) receptor selectively on fibroblasts (TRIIk-fib).
These mice develop dermal and pulmonary fibrosis. In
the present study we explore activation of TGF signal-
ing pathways in this strain and examine the profibrotic
properties of explanted transgenic fibroblasts including
myofibroblast differentiation and abnormal metallopro-
teinase production. Gene expression profiles of litter-
mate wild type or transgenic fibroblasts were compared
using high-density gene arrays and validated by Taq-
man reverse transcriptase-PCR, Northern and Western
blotting. Using a specific inhibitor (SD-208) we demon-
strate that the abnormal phenotype of these cells is de-
pendent upon TRI kinase (ALK5) activity, and that
transgenic fibroblasts show enhanced expression and
activation of TGF together with increased levels of
wild type TRII. Moreover, we confirm that transgene
expression is itself regulated by TGF and that expres-
sion at low levels facilitates signaling, whereas high
level expression is inhibitory. For a subset of TGF re-
sponsive genes basal up-regulation is normalized or sup-
pressed by exogenous recombinant TGF1 at time
points coincident with increased transgene expression.
These findings explain the profound refractoriness of
TRIIk-fib fibroblasts to exogenous TGF1, despite
their activated phenotype. Thus, transgenic fibroblasts
recapitulate many hallmark biochemical properties of
fibrotic cells, including high level CTGF (CCN2) expres-
sion and type I collagen overproduction, altered MMP
production, and myofibroblast differentiation. These
cells also show an enhanced ability to contract collagen
gel matrices. Our study demonstrates that altered high
affinity TGF receptor function may lead to ligand-de-
pendent activation of downstream signaling, and pro-
vides further evidence of a pivotal role for sustained
TGF overactivity in fibrosis.
A growing body of evidence implicates overactivity of trans-
forming growth factor  (TGF)1 in fibrosis (1, 2) leading to
sustained extracellular matrix overproduction and promoting
myofibroblast differentiation (3–5). For example, the prototypic
multisystem fibrotic disease systemic sclerosis (SSc) has been
associated with increased activity of TGF signaling pathways
(6, 7), altered expression of high and low affinity TGF recep-
tors (8–11), and autocrine overproduction of several TGF-
regulated genes (12, 13). In addition, several recent studies
suggest altered expression of TGF pathway signaling inter-
mediates in SSc including Smad3 and Smad7 (14, 15), although
the precise nature of altered Smad expression is unclear (re-
viewed in Ref. 6). Gene profiling or PCR-based differential
display experiments comparing SSc with healthy control der-
mal fibroblasts point toward a gene expression pattern for SSc
similar to that of TGF-activated normal fibroblasts (16–18).
Finally, myofibroblasts are more frequent in SSc skin and lung
samples and the myofibroblast phenotype is maintained in
explanted cultures from SSc skin or lung biopsies (19).
We have sought to directly test in vivo the hypothesis that
sustained alteration in TGF signaling or responsiveness in
fibroblasts may recapitulate the SSc phenotype. Transgenic
mice have been generated for these experiments using a potent
fibroblast-specific promoter subcloned from the pro-2(I) colla-
gen gene (20) to drive expression of TGF receptors. Surpris-
ingly, we achieved our goal of sustained activation of TGF
signaling by expressing a kinase-deficient type II TGF recep-
tor (TRIIk) in fibroblasts. Initial characterization of a novel
transgenic mouse strain in which TRIIk is expressed selec-
tively on fibroblasts by linking it a lineage-specific promoter
demonstrated development of skin and lung fibrosis (21). Our
findings were unexpected because kinase-deficient TGF re-
ceptors have previously been shown to be dominant negative
inhibitors of signaling in several experimental systems, albeit
at high expression levels compared with wild type receptors
(22). In the present study the fibrotic phenotype of explanted
dermal fibroblasts from TRIIk-fib mice is delineated. We
determine that expression of the mutant receptor leads to
multilevel activation of the TGF ligand-receptor axis and that
* This work was supported by grants from the Arthritis Research
Campaign (UK), Raynaud’s and Scleroderma Association, the Wellcome
Trust, and the Oliver Bird Fund (Nuffield Foundation). The costs of
publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement”
in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ To whom correspondence should be addressed: Centre for Rheuma-
tology, Royal Free and University College Medical School, Rowland Hill
St., London NW3 2PF, United Kingdom. Tel./Fax: 44-20-7794-0432;
E-mail: c.denton@medsch.ucl.ac.uk.
1 The abbreviations used are: TGF, transforming growth factor ;
-SMA, -smooth muscle actin; MMP, matrix metalloproteinase; FPCL,
fibroblast-populated collagen gel lattice; SSc, systemic sclerosis; PAI-1,
plasminogen activator inhibitor; PBS, phosphate-buffered saline;
PIPES, 1,4-piperazinediethanesulfonic acid; RT, reverse transcriptase;
TIMP, tissue inhibitor of metalloproteinase.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 280, No. 16, Issue of April 22, pp. 16053–16065, 2005
© 2005 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org 16053









activation is dependent upon endogenous TRI receptor kinase
activity. Two cardinal features of this mouse strain are identi-
fied: altered metalloproteinase expression and function, and
myofibroblast differentiation. In addition, we confirm that the
fibroblast-specific expression cassette is itself regulated by
TGF and that low level expression of the kinase-deficient
TRII activates TGF signaling, whereas higher expression
levels are inhibitory. We hypothesize that the profound refrac-
toriness of explanted transgenic dermal fibroblasts to recombi-
nant TGF1 is because of transgene up-regulation in ligand-
activated cells. It is possible that analogous signaling
perturbations may lead to balanced up-regulation of profibrotic
pathways and sustain abnormal fibroblast properties in fibrotic
disease. If so, then consequences of blocking TGF ligand or
receptor activity are unpredictable, and animal models such as
the TRIIk-fib strain are likely to be valuable tools in the
development and evaluation of targeted antifibrotic therapies.
EXPERIMENTAL PROCEDURES
Transgenic Mice—The generation and initial characterization of the
transgenic mice strains used in this work has been previously described.
In brief, a fibroblast-specific expression cassette was subcloned from the
upstream region of the pro-2(I) collagen gene (Col1a2). This incorporates
a fragment between 19.5 and 13.5 kb upstream of the transcription
start site that, when linked to an endogenous minimal promoter drives
gene expression at high levels in fibroblasts, but not in other type I
collagen producing cells. Reporter genes linked to this promoter-enhancer
show high level fibroblast-specific expression in embryonic development
from 8-day post-conception and postnatally, as previously described. The
mouse strain TRIIk-fib was generated by subcloning the cDNA encod-
ing the extracellular and transmembrane portion of the human type II
TGF receptor into the SalI site of the pCD3 expression vector. A bacterial
-galactosidase gene (LacZ) is coexpressed from a dicistronic transgene
mRNA product via an encephalomyocarditis virus internal ribosome
entry site sequence. Full details of this construction are provided in
Ref. 21. Fibroblasts cultured from 6-kb LacZ transgenic mice, in
which a bacterial -galactosidase reporter gene is regulated by the
same fibroblast-specific reporter transgene as the TRIIk-fib strain
were used in control experiments (23).
Fibroblast Culture—Fibroblast cultures were derived from skin bi-
opsies from the lower back of neonatal transgenic or control littermate
mice. Cells were cultured in the presence of antibiotics and passaged at
confluence. Fibroblasts were maintained in Dulbecco’s modified Eagle’s
medium (Invitrogen) supplemented with 10% fetal calf serum (Invitro-
gen), 100 units/ml penicillin, 100 mg/ml streptomycin, and cultured in
a humidified atmosphere of 5% CO2 in air. Fibroblasts were subcul-
tured at confluence and used between passages 2 and 5. Fibroblast
monolayer cultures were incubated for 16–24 h in serum-free culture
medium prior to experiments examining agonist effects. Transgene
expression levels were routinely measured by the GalactolightTM bio-
chemical assay of -galactosidase activity (Tropix Inc., Bedford, MA),
with normalization of assay data for cell number by assessing DNA
concentration in cell or tissue lysates (23).
Transfection of Neonatal Fibroblasts—To assess TGF1 signaling
pathway activity or responsiveness a series of TGF-regulated promot-
er-reporter constructs were introduced into transgenic or wild type cells
by transient transfection, and the effect of recombinant TGF1 on
reporter gene expression determined. Constructs used for these exper-
iments have been previously described, including PAI-1 (24), Col1a2
(23), and a trimeric sequence delineated as the TGF response element
of the PAI-1 promoter, designated 3TP (25). All were linked to a firefly
luciferase reporter and plasmids were transfected into neonatal fibro-
blasts using Lipofectamine PlusTM (Invitrogen) according to the man-
ufacturer’s instructions. Assessment of luciferase activity was by the
Dual LightTM reporter gene system (Tropix Inc.) with a 1:100 pSV40-
LacZ control plasmid. For experiments 70% confluent fibroblast mono-
layers were used in 24-well tissue culture plates. To determine the
effect of TRIIk co-expression on activity, the cDNA encoding
TRIIk was subcloned into pCDNA3 (Invitrogen) and cotransfected at
concentrations between 10 and 200 ng/tissue culture well with each of
these TGF-regulated promoter-reporter constructs. Later, to investi-
gate the responsiveness of the fibroblast-specific promoter-enhancer
cassette driving TRIIk a series of experiments were performed in
which a pCMV-Smad7 was transfected into transgenic fibroblasts from
the 6-kb LacZ mouse strain or wild type fibroblasts cotransfected with
a plasmid in which the minimal endogenous promoter was replaced by
a non-TGF responsive herpes simplex virus-thymidine kinase pro-
moter as described previously (23).
Western Blot Analysis of Fibroblast Protein Expression—To examine
biochemical or functional differences between transgenic or wild type
fibroblast cultures and compare responsiveness to recombinant TGF1
ligand Western blot analysis was performed. Cell layer lysates and
tissue culture supernatants were examined from independent strains
derived from transgenic or non-transgenic littermates (n  5). Super-
natants were concentrated by ammonium sulfate precipitation to selec-
tively enrich samples for secreted matrix proteins. After SDS-PAGE,
proteins were electroblotted onto nylon membranes and probed with
specific antibodies. These were localized by chemiluminescence using a
specific secondary antibody. For supernatants, specific antibodies to
collagen type I (Southern Biotechnology Inc., Birmingham, AL) were
used. Other studies examined CTGF (R&D Systems) and MMP13,
TRI, TRII, and phosphorylated Smad2/3 (Santa Cruz Biotechnology,
Santa Cruz, CA) using specific primary antibodies. Mouse-specific pri-
mary antibodies were used to ensure that endogenous TRII rather
that truncated TRIIk was detected.
Northern Blot Analysis—Total RNA was isolated from fibroblasts
using the isothiocyanate/cesium chloride method (26) or by TRIzol
(Invitrogen) according to the manufacturer’s instructions. Levels of
specific transcripts were determined by Northern blotting, following
separation of RNA on 1% agarose gels containing 2.2 M formaldehyde
and capillary transfer to Hybond N membrane (Amersham Bio-
sciences). Filters were hybridized and probed with cDNA fragments
specific for pro-2(I) collagen and CTGF mRNAs as previously de-
scribed (12). 18 S rRNA band intensity was used to confirm equal gel
loading. Probes were labeled with [-32P]dCTP to a specific activity of
109 dpm/mg, using the MegaprimeTM random priming method (Amer-
sham Biosciences). Levels of transcripts were determined from signal
intensity measured by autoradiography.
Pharmacological Inhibitor Studies—Pharmacological inhibitors and
anti-TGF antibodies were used to explore the role of key components
of the ligand-receptor axis in determining the abnormal properties of
transgenic fibroblasts. A novel, highly specific, inhibitor of the TRI
kinase (SD-208, Scios Inc., Fremont CA) was used to ask whether
blocking endogenous TGF signaling would abrogate the increase in
TGF-dependent gene and protein expression in transgenic cells. SD-
208 has an IC50 of 49 nmol/liter based on direct enzymatic assay of
TGFRI kinase (ALK5) activity with a specificity of 100-fold against
TGFRII and at least 17-fold over members of a panel of related protein
kinases including p38a, p38b, p38d, JNK1, EGFR, MAPKAPK2, MKK6,
ERK2, PKC, PKA, PKD, CDC2, and CaMKII. Preliminary experiments
defined the effective concentration producing specific ALK5 inhibition.
For these experiments fibroblasts were cultured to confluence, incu-
bated in a low serum medium overnight, and then stimulated with
recombinant TGF1 (4 ng/ml) for between 30 min and 24 h, in the
presence or absence of the novel inhibitor. For studies examining reg-
ulation of the fibroblast-specific expression cassette by TGF1, mithra-
mycin was used to inhibit Sp1 (27) and curcumin was used as an
inhibitor of AP-1 (28). In some experiments the broad spectrum metal-
loproteinase inhibitor GM6001 was used to block protease activity in
monolayer or gel lattice culture (29). To assess the effect of neutralizing
antibody against TGF (1D11) on transgene expression in TRIIk-fib
mice, neonatal animals were injected with 1D11 or the isotype-matched
control monoclonal 13C4 (2.5 mg/kg intraperitoneal) and -galactosid-
ase activity assayed in tail biopsy lysate 48 h later.
Quantitative RT-PCR Methods—Fluorescent real-time PCR (Taq-
man) was used to confirm basal and TGF1-induced differences in gene
expression. Total RNA was extracted and treated with RNase-free
DNaseI, (Roche, Lewes, UK) for 10 min at 37 °C and heat inactivation
at 70 °C for 15 min. 1 g of total RNA was reverse transcribed using 2
g of random hexamers (Amersham Biosciences) and 200 units of
Superscript II reverse transcriptase (Invitrogen). Quantitative PCR
were done on the ABI Prism 7700 (Applied Biosystems, Warrington,
UK) according to previously described methods, with each reaction
containing 5 ng of reverse transcribed RNA in 25 l. 18 S rRNA
(primers and probes from Applied Biosystems) were used as an endog-
enous control to account for differences in the extraction and reverse
transcription of total RNA.
Affymetrix Genechip Experiments—Total RNA was harvested from
confluent fibroblast monolayers (TRIzol, Invitrogen) and quantified,
and integrity was verified by denaturing gel electrophoresis. Equal
amounts of identically treated RNA were pooled and reverse tran-
scribed (Invitrogen) into cDNA that was then in vitro transcribed into
biotinylated cRNA. The target cRNA was then fragmented and hybrid-
Fibrotic Mechanisms in TRIIk-fib Transgenic Mice16054









ized to the mouse U74Av2 array (Affymetrix, Santa Clara, CA), cover-
ing 12,000 mouse genes, as described by the manufacturer. Hybridiza-
tion of cRNA, signal amplification, and data collection were performed
using a fluidics station and chip reader following the AffymetrixTM
protocol. Arrays were scaled to an average intensity of 100 per gene and
analyzed using the Affymetrix Microarray Analysis Suite version 5.0.
Briefly, transcripts were defined as up-regulated or down-regulated
only when identified as “present” and as significantly different (p 
0.001) in two independently probed genechip pairs. The -fold change
between treated and untreated samples had to be at least 2.5-fold to
designate a transcript as being differentially expressed.
Contraction of Free-floating or Fixed Fibroblast Populated Collagen
Lattices—To study collagen gel contraction, fibroblasts were cultured
within three-dimensional collagen lattices (fibroblast populated colla-
gen lattices; FPCL). These were prepared as previously described (30).
In brief, 24-well tissue culture plates (Costar) were pre-coated with
sterile 2% bovine serum albumin in phosphate-buffered saline (PBS) (2
ml/well) by incubation at 37 °C overnight, and were then washed three
times with sterile PBS. For FPCL, neutral collagen solution (containing
one part of 0.2 M HEPES, pH 8.0; four parts collagen (Vitrogen-100, 3
mg/ml, Celltrix, Santa Clara, CA) and five parts of MCDB 104 medium
(Sigma, 2 times concentrate) was prepared and mixed with fibroblasts
that were resuspended in 2 times MCDB 104 medium, to bring the final
concentration to 80,000 cells and 1.2 mg of collagen/ml. The collagen-
cell suspension (1 ml) was added to each well, and allowed to solidify for
1 h. After polymerization, 1 ml of MCDB medium was added to each
well, causing detachment of the lattice from the tissue culture plastic,
yielding free-floating FPCLs.
Measurement of tension across a three-dimensional, free-floating
fibroblast-populated collagen lattice was performed as described previ-
ously (31, 32). Briefly, with 1  106 cells/ml collagen gel, we measured
the force generated across the collagen lattice, by using a tensioning
culture force monitor that is capable of measuring the minute forces
exerted by cells within a collagen lattice over 24 h as fibroblasts attach,
spread, and migrate. The rectangular fibroblast-seeded collagen gel was
cast and floated in medium, tethered to two flotation bars on either end
of the short edges, in turn attached to an anchor point at one end and
a force transducer at the other. Cell-generated tensional forces in the
collagen gel were detected by the force transducer and logged into a
personal computer. Graphical readings are produced every 10 min,
averaged from 600 readings (1 per second), providing a continuous
output of force (Dynes) generated (31).
Immunostaining of Cells and Tissues—Cells were seeded at 4  103
cells/well in Dulbecco’s modified Eagle’s medium, 10% normal calf se-
rum into chamber slides (Labtek, Nunc; Fisher Scientific UK, Lough-
borough, UK), grown to subconfluence, made quiescent in serum-free
Dulbecco’s modified Eagle’s medium overnight, and exposed to control
media (Dulbecco’s modified Eagle’s medium) or recombinant TGF1 (4
ng/ml) for between 3 and 24 h. Parallel experiments were performed
with SD-208 to block TRI kinase (ALK5) activity. The cell monolayer
was washed three times with PBS, and fixed in 4% formaldehyde for 5
min. Cells were washed three times in PBS before permeabilization and
after each later step. Permeabilization was performed using 0.1% Tri-
ton in 50 mM PIPES (pH 7.0), 90 mM HEPES (pH 7.0), 0.5 mM MgCl2,
0.5 mM EGTA, and 75 mM KCl for 30 s, at room temperature. Chamber
slides were incubated with primary antibody specific for phosphoryl-
ated Smad2/3 (Santa Cruz Biotechnology, Santa Cruz, CA) to examine
receptor-regulated Smad activity and localization. Other studies used
anti-SMA specific antibody (Santa Cruz Biotechnology). After incuba-
tion with primary antibody or irrelevant control, serum slides were
treated with a fluorescein-labeled anti-mouse antibody (Jackson Immu-
noResearch Laboratories, West Grove, PA), each for 60 min at room
temperature. Nuclei were stained for 1 min in 1 g/ml 4,6-diamidino-
2-phenylindole (Molecular Probes, Eugene, OR). After extensive wash-
ing with PBS, a single drop of CitiFluor AF1 (Chem Lab, Canterbury,
UK) was added and cells were then visualized and photographed using
an Axioskop Z fluorescence microscope (Carl Zeiss, Jena, Germany). For
immunolocalization of TGF in neonatal mouse, skin samples from
TRIIk transgenic or wild type littermates were skin snap frozen.
Serial frozen sections (5 m) were cut on a cryostat at 30 °C and
air-dried for 1 h. Sections were fixed in ice-cold acetone and covered
with 3% hydrogen peroxide for 10 min in the dark to block endogenous
peroxidase activity. Slides were then blocked with 20% normal horse
serum, and incubated with monoclonal antibody against TGF (1D11)
for 1 h at room temperature. Primary antibody was localized using a
biotin/streptavidin-based amplifying system. After washing with PBS,
sections were incubated with biotinylated rabbit anti-mouse IgG di-
luted in PBS (7.5 g/ml, BA-9500; Vector Laboratories) for 30 min,
rinsed, and finally incubated with Vectastain Elite STR-ABC reagent
(Vector Laboratories) for 30 min. Immunolocalization was visualized
using 3-amino-9-ethylcarbazole chromogen and H2O2 as substrate (SK-
4200; Vector Laboratories). Sections were then washed in tap water,
counterstained with Carrazzis hematoxylin, and mounted with Gel-
mount (Biomeda, Foster City, CA). Specificity of staining was confirmed
in control sections incubated with an isotype-matched irrelevant control
antibody (13C4) in place of 1D11.
TGF- Bioassay Using Mink Lung Epithelial Cells—To examine
TGF bioactivity in fibroblast culture supernatants we used a validated
bioassay incorporating mink lung epithelial cells stably transfected
with a PAI-1 luciferase reporter construct. The assay was performed as
described previously (24). For each supernatant, aliquot basal activity
(active TGF) and activity after heating the supernatant at 80 °C for 10
min (total TGF) was compared. Samples were analyzed in triplicate.
Briefly, 1.6  104 per well were plated in 96-well tissue culture dishes.
After attachment for 3 h at 37 °C in 5% CO2, medium was replaced by
test sample and after 14 h at 37 °C luciferase activity was determined.
Recombinant TGF1 and neutralizing anti-TGF antibody (1D11) or
isotype matched irrelevant antibody (13C4) were used to verify speci-
ficity of the assay. Equal numbers of transgenic or wild type cells were
seeded at baseline and luciferase expression data were expressed per
unit supernatant volume. Equivalent transgenic or wild type cell num-
ber at the time of harvesting the supernatant was confirmed by direct
counting.
Statistical Analysis—For quantitative variables, mean (S.E.) in
replicate samples or combined independent experiments, where inter-
experiment variation allowed reliable combination of raw data, were
compared. Means were compared by Student’s paired or unpaired t test
as appropriate and p  0.05 taken as statistically significant.
RESULTS
Profibrotic Phenotype of TRIIk Transgenic Fibroblasts—
We have generated transgenic mice that develop dermal and
sporadic pulmonary fibrosis using a fibroblast-specific expres-
sion cassette to direct expression of a kinase-deficient type II
TGF receptor (21). The basis for paradoxical activation of
fibrotic mechanisms by a non-signaling receptor is the focus of
the present study. Our initial experiments confirmed basal
overproduction of pro(I) collagen compared with littermate wild
type cells and also demonstrated sustained refractoriness of
neonatal transgenic fibroblasts to recombinant TGF1 (Fig.
1A). We also observed constitutive expression of CTGF (CCN2,
FISP12) protein by transgenic fibroblasts compared with litter-
mate wild type cells. To confirm that activation of the TGF
signaling pathway determined constitutive overexpression of
pro(I) collagen or CTGF, SD-208, a novel TRI-kinase (ALK5)
inhibitor was used. Inhibition of ALK5 reduced pro(I) collagen
and CTGF expression in transgenic fibroblasts to levels seen in
littermate wild type cells (Fig. 1B). In parallel experiments,
mRNA levels of pro-2(I) collagen and CTGF were reduced to
wild type levels in transgenic fibroblasts following treatment
with the inhibitor SD-208 (Fig. 1C). We also examined expression
of the major type I collagen degrading enzyme MMP13 in mice.
Levels of both precursor and active enzyme were substantially
increased in transgenic fibroblast compared with littermate wild
type cells, suggesting that protein overproduction rather than
reduced degradation is more likely the cause of increased matrix
collagen in the TRIIk-fib transgenic mice (Fig. 1D).
We hypothesized that expression of TRIIk on fibroblasts
may alter basal levels of endogenous wild type TGF receptors.
A series of Western blot experiments using mouse-specific pri-
mary antibodies confirmed substantially increased levels of
wild type TRII in transgenic fibroblast lysates. This provides
a plausible explanation for increased TGF signaling in these
cells. Levels of wild type TRI were not altered in transgenic
fibroblasts (Fig. 2A). Later, we confirmed that transgenic fibro-
blasts but not wild type cells demonstrated nuclear staining for
phosphorylated Smad2/3 (Fig. 2, B and C). Consistent with pre-
vious observations concerning the refractoriness of TRIIk-fib
cells to recombinant TGF1, while there was a marked nuclear
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localization of pSmad2/3 in wild type fibroblasts 10 min after
TGF1 activation, no change in staining occurred in littermate
transgenic fibroblasts (Fig. 2, D and E). Western blot analysis
of wild type or transgenic fibroblast lysates confirmed in-
creased Smad2/3 phosphorylation in TRIIk-fib, and also its
dependence upon ALK5 activation because it is abrogated by
SD-208 (Fig. 2F).
Global Expression Profiling of TRIIk Transgenic Fibro-
blasts—Based upon the similarity in phenotype between the
TRIIk-fib mouse strain and human scleroderma (SSc) we
were interested in exploring the similarity between the gene
expression profile of transgenic fibroblasts and that reported in
a number of earlier studies of dermal fibroblasts from SSc (12,
13, 17). In these reports genes that are overexpressed or down-
regulated have generally supported a role for TGF in SSc
pathogenesis (33). In the present study we have used high
density oligonucleotide genechips to compare gene expression
for transgenic or littermate wild type fibroblasts in a series of
independent experiments. Our data confirm that the gene ex-
pression profile of transgenic fibroblasts replicates many re-
ported features observed in chronic fibrotic fibroblasts. Using
the MAS5.0 gene expression profiling software (Affymetrix)
independent analysis of two pairs of transgenic fibroblasts and
non-transgenic littermates identified 5846 expressed genes. Of
these, 297 were up-regulated at least 2-fold and 420 genes were
down-regulated 2-fold. These genes included a range of matrix
components, cytokines, growth factors, and signaling interme-
diates consistent with the complex profibrotic phenotype pre-
viously reported for these transgenic fibroblasts. In our analy-
sis of these profiles we have concentrated on genes that are
more than 2.5-fold differentially expressed. Overexpressed
genes (n  41) are listed in Table I and down-regulated genes
are listed in Table II (n  21). Transcript levels of a number of
growth factors increased, including several that promote fibro-
sis through activation of fibroblasts (interleukin-6, platelet-
derived growth factor-A, and Cyr61, and perhaps most signifi-
cantly TGF1). Two of the most overexpressed transcripts,
PAI-1 (14.7-fold) and CCN2/CTGF (11.5-fold), are prototypic
markers of TGF activation, consistent with our hypothesis
that these transgenic fibroblasts have sustained activation of
TGF signaling pathways. Other TGF up-regulated genes
were thrombomodulin, osteoprotegerin, and OSF1. A number
of potentially important genes were down-regulated in trans-
genic fibroblasts (see Table II), including growth factors such
as insulin-like growth factor 1, insulin-like growth factor 2,
CCL11, and SDF1.
FIG. 1. Biochemical phenotype of TRIIk-fib dermal fibro-
blasts. A, pro(I) collagen overexpression and refractoriness to TGF1
demonstrated by Western blot analysis of dermal fibroblast superna-
tants after stimulation by recombinant murine TGF1 (4 ng/ml). B,
collagen and CTGF protein overexpression is abrogated by TRI kinase
(ALK5) inhibition (SD-208). C, Northern blot analysis shows Col1a2
and CTGF mRNA overexpression is abrogated by TRI kinase inhibi-
tion (SD-208).D, transgenic (tg) fibroblasts overexpress the major fibril-
lar collagen-degrading protease MMP-13. Results shown are represent-
ative of a series of four independent experiments. wt, wild type.
FIG. 2. TRIIk-fib dermal fibroblasts have increased levels of
endogenous TRII and altered phosphorylation of Smad2/3. A,
Western blot analysis of littermate fibroblast pairs confirms increased
levels of endogenous TRII in transgenic (tg) cells using a mouse-
specific primary antibody. Levels of TRI were not significantly differ-
ent. Coomassie-stained polyacrylamide gel confirms equal protein load-
ing. Nuclear staining of phosphoryated Smad2/3 (arrow) is absent in
wild type (wt) fibroblasts (B) but present in transgenic TRIIk-fib cells
(C). There is strong staining of wild type nuclei 10 min after incubation
with recombinant TGF1 (4 ng/ml) (D) but transgenic fibroblasts show
no change (E). Western blot analysis of wild type or transgenic fibro-
blast lysates confirmed increased Smad2/3 phosphorylation in
TRIIk-fib, and its dependence upon ALK5 activation because it is
abrogated by SD-208 (F). Data are representative of a series of three
independent experiments.
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Down-regulated genes in TRIIk transgenic fibroblasts (Affymetrix U74v2)
Affymetrix tag Accession No. TRIIk Wild typea -Fold change Gene
95545_at U22399 1218.1 53.8 22.6 Cyclin-dependent kinase inhibitor 1C
94813_at X65128 1299.9 226.2 5.7 Growth arrest specific 1
101095_at L23769 516.65 95.3 5.4 Microfibril-associated glycoprotein
93028_at X58196 3997.2 759.35 5.3 H19 fetal liver mRNA
93511_at L38971 511.05 115.6 4.4 Integral membrane protein 2
92365_at X99572 682.3 165.4 4.1 Secreted frizzled related protein sFRP-2 (Sfrp2)
93503_at U88567 206.5 52.65 3.9 Lysosomal-associated protein transmembrane 5
99010_at AB24538 415.45 116.75 3.6 Immunoglobulin superfamily containing leucine-rich repeat)
96195_at U57686 194.85 59.05 3.3 Embryonal Fyn-associated substrate p130 Cas-related protein Sin
102691_at A1848518 308.85 97.7 3.2 UI-M-AP1-agf-e-02-0-UI.s2
103030_at L31397 651.95 207.1 3.1 Dynamin
103031_at L31397 954 322.95 3.0 Dynamin
160511_at L12029 657.65 227.3 2.9 Chemokine (C-X-C motif) ligand 12, stromal cell-derived factor 1
103492_at AF077738 293.55 105.5 2.8 Metallocarboxypeptidase CPX-1
93324_at M58566 579.8 212.9 2.7 Zinc finger protein 36
98088_at X13333 443.15 163.2 2.7 CD14 antigen
93353_at AF013262 1215.55 448.6 2.7 Lumican
93343_at J03952 1709.9 642.85 2.7 Glutathione transferase
9531_at A1854771 193.75 73.1 2.7 UI-M-BH0-aka-c-100-UI.s1
99622_at U20344 395.15 152.5 2.6 Kruppel-like factor 4 (gut), gut-enriched Kruppel-like factor
102395_at Z38110 931.85 364.7 2.6 PMP22 mRNA for peripheral myelin protein
a Mean expression determined from two independently performed experiments using the Affymetrix U74v2 genechips. Genes were determined
as present in all samples and designated significantly down-regulated (p 0.001) in both transgenic samples compared with wild type littermates.
TABLE I
Up-regulated genes in TRIIk transgenic fibroblasts compared with wild type littermates (Affymetrix U74v2)
Affymetrix ID Accession No. Wild typea TRIIka -Fold change Descriptions
94147_at M33960 147.9 2181.6 14.7 PAI-1
93294_at M70642 207.8 2394 11.5 CTGF (CCN-2, FISP12), fibroblast-inducible secreted protein
104467_at M88242 85.5 906.65 10.6 Mouse glucocortoid-regulated inflammatory prostaglandin
G/H synthase
100277_at X69619 148.6 1405.6 9.5 Inhibin -A
98865_at U52554 64.7 512.9 7.9 Hyaluronan synthase 2
94378_at U94828 113.6 878.2 7.7 Mus musculus retinally abundant regulator of G-protein
signaling mRGS-r
96055_at X59520 88.4 517.5 5.9 Cholecystokinin
93550_at d88792 102.95 554.2 5.4 Cysteine and glycine-rich protein 2
102218_at X54542 67.75 351.2 5.2 Interleukin 6
103065_at M73696 111.75 533.6 4.8 Solute carrier family 20, member 1, murine Glvr-1
102663_at X62700 31.05 144.4 4.7 Urokinase oplasminogen activator receptor M. musculus
muPAR1
100554_at AF053367 108.95 501.85 4.6 PDZ and LIM domain 1 (elfin) carboxyl-terminal LIM
domain protein
92730_at L07264 79.15 364.45 4.6 Heparin binding epidermal growth factor-like growth factor
93883_at K03235 224.8 1000.9 4.5 Proliferin
94383_at D50586 79.2 351.8 4.4 Tissue factor pathway inhibitor 2
103039_at X79003 74.1 326.5 4.4 Integrin 5 (fibronectin receptor )
101393_at AJ001633 206.8 792.6 3.8 Annexin III
92571_at D85904 100.35 369.8 3.7 Heat shock protein 4, mouse mRNA for apg-2
92310_at M96163 439.3 1473.0 3.4 Serum inducible kinase (SNK)
92777_at M32490 88.15 284.6 3.2 Cyr61, insulin-like growth factor binding protein 10
101551_at X78989 76.8 246.1 3.2 Testin
101979_at AF055638 167.5 531.25 3.2 Growth arrest and DNA-damage-inducible 45
99942_s_at U28923 155.5 491.95 3.2 Smooth muscle calponin gene
97535_at D87661 180.4 549.65 3.0 mRNA for 14-3-3 eta
100026_at U42443 237.15 721.8 3.0 MECA39
160829_at U44088 106.15 315.4 3.0 FasL synthesis, pleckstrin homology-like domain, family A,
member 1
100381_at M12347 199.3 577.85 2.9 Actin, 1, skeletal muscle
101918_at M17298 62.95 182.2 2.9 Transforming growth factor-1
102298_at M17298 55.85 161.0 2.9 Nerve growth factor, 
96701_at U35823 230.45 660.9 2.9 Ubiquitin-like 1 (sentrin) activating enzyme E1B
96657_at L10244 353.5 1011.9 2.9 Spermidine/spermine N1-acetyltransferase
160102_at Z237164 132.95 375.2 2.8 M. musculus chaperonin subunit 8 (theta) Cctq
94932_at M29464 180.75 496.4 2.7 Platelet-derived growth factor 
101973_at y15163 132.15 357.9 2.7 Cbp/p300-interacting transactivator
102887_at U94331 91.8 245.9 2.7 Osteoprotegerin (OPG)
94288_at J03482 241.3 645.3 2.7 Histone H1 gene
95580_at U39473 83.85 223.6 2.7 Histidyl-tRNA synthetase
104601_at X14432 161.4 423.3 2.6 Thrombomodulin
99158_at U58888 159.4 416.3 2.6 Osteoclast stimulating factor 1
94826_at Y11460 96.2 250.55 2.6 4 Integrin interactor
101096_s_at AF203482 80.55 209.15 2.6 Nidogen 2
a Mean expression determined from two independently performed experiments using the Affymetrix U74v2 genechips. Genes were determined
as present in all samples and designated significantly up-regulated (p  0.001) in both transgenic samples compared with wild type littermates.
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Myofibroblast Differentiation in Transgenic Dermal Fibro-
blast Cultures—Gene expression profiling identified consistent
up-regulation of a several transcripts characteristic of a myo-
fibroblast phenotype including calponin (3.2-fold) and myosin
heavy chain (1.7-fold). This led us to explore differences in
expression of -smooth muscle actin (-SMA) in transgenic
fibroblasts. Gene and protein expression levels in cell lysates
did not significantly differ between wild type and transgenic
fibroblasts but immunostaining of cultured cells was strikingly
different. There was basal expression of -SMA in transgenic
fibroblasts (Fig. 3, A and B) with formation of a myofibril-rich
cytoskeleton. Wild type littermate fibroblasts responded to re-
combinant TGF1 by forming -SMA-rich fibers, whereas
there was no change in -SMA expression by transgenic
fibroblasts in response to TGF1 (Fig. 3, C and D). The novel
TRI kinase (ALK5) inhibitor SD-208 inhibited -SMA fila-
ment formation in both transgenic or wild type fibroblasts
treated with TGF (Fig. 3, E and F). In transgenic fibroblasts
SD-208 altered the constitutive pattern of -SMA staining
leading to fragmentation or condensation of myofibrils,
whereas basal expression in wild type cells was not altered
(Fig. 3, G and H)).
Metalloproteinase Expression and Regulation by TGF-1 Is
Altered in Transgenic Fibroblasts—The marked differences in
MMP13 protein expression between transgenic and wild type
fibroblasts and potential contribution of altered metallopro-
teinase expression to the development of fibrosis prompted a
systematic analysis of MMP and TIMP gene expression. We
first asked whether expression of collagen-degrading enzymes
was reduced or if levels of the inhibitors of MMP activity
TIMP1, -2, and -3 increased. Expression levels for the MMP
and TIMP genes included on the U74v2 genechip are summa-
rized in Table III. Based upon these results, we undertook
quantitative real time RT-PCR analysis using a series of 5
paired littermate samples. There were clear differences be-
tween transgenic and wild type cells with respect to MMP gene
and protein expression, consistent with the importance of met-
alloproteinases in connective tissue remodeling and their reg-
ulation by TGF. MMP3, -9, -10, -13, and TIMP1 were up-
regulated in transgenic fibroblasts (Fig. 4A). Conversely,
MMP7 and MMP11 were down-regulated (Fig. 4B). Although,
the quantitative PCR results were consistent for all littermate
pairs of fibroblasts examined, the Affymetrix genechip data
were less clear: there was considerable discrepancy between
the data from each paired comparison and together none
reached the 2.5-fold threshold for differential expression used
in this study. We suspect that these discrepant results may
reflect the complexity of regulation of MMP and TIMP genes by
TGF and the limitations of simple comparison of mRNA levels
in unstimulated fibroblast cultures. To clarify whether differ-
ences in basal expression could be explained by differences in
TGF pathway activation, additional time course analyses
were performed using transgenic or wild type fibroblasts after
stimulation with recombinant TGF1. Transcripts for MMP-3,
MMP-9,MMP-13, and TIMP1 were strongly induced by 12 h in
wild type fibroblasts (Fig. 4, C–F). In transgenic fibroblasts
there was basal overexpression but no significant induction of
these genes in response to TGF1. Unexpectedly,MMP-13 and
MMP-3 transcripts, while elevated at 3 and 6 h compared with
wild type, were suppressed to basal wild type levels in trans-
genic cells at 12- and 24-h time points. Together these obser-
vations suggest that despite the general refractoriness of trans-
genic fibroblasts to TGF, for some genes there is regulation
and for these inhibitory pathways may be preferentially acti-
vated in transgenic fibroblasts in response to exogenous
TGF1. Later experiments strongly suggest that dominant
negative activity of TRIIk transgene expressed at higher
levels from 24 h was important in this context (see below).
Transgenic Fibroblasts Show Enhanced Remodeling and
Contraction of Fibroblast-populated Collagen Lattices—Based
upon the altered MMP expression and apparent contractile
phenotype of transgenic fibroblasts implied by expression of a
mature -SMA containing cytoskeleton we examined contrac-
tion of FPCL by transgenic cells. First we used a tensiometer
system that allows force generated by fibroblasts to be meas-
ured as they contract the lattice (Fig. 5A). Force generation in
the fibroblast-populated collagen lattice has previously been
shown to depend upon both remodeling of the lattice together
with contraction of cells within the gel matrix. Lattice contrac-
tion continued at a much faster rate and with greater gel
tension for transgenic fibroblasts compared with equal num-
bers of seeded littermate wild type fibroblasts. This is consist-
ent with more myofibroblasts being present in cultures from
transgenic skin. There was also greater contraction of free-
floating collagen lattices by transgenic fibroblasts (Fig. 5B).
Previously, it has been demonstrated for wild type dermal
fibroblasts that free-floating gel contraction depends mainly
upon lattice remodeling (31) that can be promoted by TGF (34)
or blocked by inhibitors of MMPs such as GM6001 (35). Our
results confirm these observations in wild type fibroblasts, but
suggest that transgenic fibroblasts are refractory to recombi-
nant TGF1 and also to GM6001 (Fig. 5C). High endogenous
levels of TGF1 and MMP activity that cannot be inhibited by
concentrations of GM6001 may underlie the refractoriness of
FIG. 3. Constitutive myofibroblast formation in vitro is abro-
gated by a specific ALK5 inhibitor. Constitutive formation of
-SMA containing myofibrils in transgenic fibroblasts confirms myofi-
broblast differentiation in serum-starved transgenic fibroblasts (A and
B). Similar expression is induced in wild type cells from 3 h by recom-
binant TGF1 (4 ng/ml) (C and D). The ALK5 inhibitor SD-208 blocks
-SMA induction (E and F) and abrogates constitutive myofibril forma-
tion in transgenic fibroblasts (G and H).
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transgenic compared with wild type fibroblasts in this experi-
mental system.
Expression and Activation of TGF- Is Enhanced in Trans-
genic Mice—To determine whether supernatants from trans-
genic fibroblasts contained higher levels of TGF bioactivity
than those from wild type cells, a bioassay using mink lung
epithelial cells harboring a TGF-regulated promoter-reporter
construct was used. Transgenic fibroblast supernatants dem-
onstrated more than 2-fold elevation of bioactive TGF com-
pared with littermate wild type cultures (Fig. 6A). Specificity of
TABLE III
Metalloproteinase gene expression in wild type and transgenic fibroblasts
Affymetrix ID Accession No. Wild type TRIIk Relativeexpressiona -Fold change Gene
98833_at X66402 247.5 385 I 1.6 MMP3
168521_at X72795 45.4 72.0 I 1.6 MMP9
94724_at Y13185 10.7 132.7 I NDb MMP10
100015_at Z12604 133.4 99.4 NC 0.7 MMP11
100016_at M82831 122.2 33.5 D 0.3 MMP12
100484_at X66473 79.7 102.6 I 1.3 MMP13
160118_at AF022432 1899.9 1527.3 NC 0.8 MMP14
92461_at AB021224 105.9 159.2 NC 1.5 MMP17
101464_at V00755 2286.0 3651.8 I 1.6 TIMP1
160116_at A1850047 269.5 156.4 NC 0.6 TIMP2
16051_at AV156389 969.2 1853.4 I 1.9 TIMP3
a Designation of expression in two independent experiments using Affymetrix U74v2 genechips. Transcripts were designated as unchanged (UC),
down-regulated (D), or up-regulated (I) in transgenic versus wild type samples by the Affymetrix™ MAS5.0 software program.
b This transcript was not present in wild type samples and so –fold change is not determined (ND).
FIG. 4. Perturbed MMP expression
and regulation in transgenic fibro-
blasts. A, basal up-regulation or down-
regulation of key MMP genes in trans-
genic (tg) fibroblasts was determined by
quantitative real-time RT-PCR. Tran-
script quantitation was measured relative
to 18 S rRNA amplification from the same
sample and data are expressed as a ratio
(-fold change) above mean basal expres-
sion for paired wild type (wt) fibroblast
samples. Data summarize at least three
independent experiments using fibro-
blasts from 5 littermate pairs. B, basal
overexpression but paradoxical down-reg-
ulation by TGF1 in transgenic fibro-
blasts was confirmed in three independ-
ent experiments using fibroblasts from
transgenic or wild type littermate pairs
(n  3) treated with recombinant murine
TGF1 (4 ng/ml) after overnight serum
starvation. For TIMP1 and MMP-9 there
was transient induction in transgenic fi-
broblasts with later return to basal ex-
pression. In contrast, MMP-3 and
MMP-13 were suppressed to basal wild
type levels at later time points.
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the assay for TGF was confirmed using anti-TGF antibody
(1D11) or an isotype-matched control monoclonal (13C4) (data
not shown). Supernatants from transgenic fibroblasts also con-
tained higher total TGF levels. These results were validated
by examining the amount of active TGF present in transgenic
fibroblast skin biopsies. Immunolocalization using a panspe-
cific anti-TGF antibody confirms increased dermal expression
of TGF1 in transgenic fibroblasts compared with littermate
wild type biopsies (Fig. 6B). An isotype-matched control anti-
body (13C4) was negative, confirming specificity of this stain-
ing. The data for total TGF were later confirmed using a
non-murine anti-TGF1 primary antibody in formalin-fixed
biopsy sections (data not shown).
In view of our finding that a number of metalloproteinases
known to activate latent TGF complex were elevated in trans-
genic fibroblast cultures, we asked whether increased TGF
bioactivity in culture supernatants might be MMP-dependent.
In a series of three independent experiments there was con-
sistent reduction in active but not total TGF activity in su-
pernatants from transgenic fibroblast cultures treated with
GM6001 (Fig. 6C). As this reduction was relatively modest in
comparison with the elevated TGF activity in these superna-
tants it is likely that other mechanisms may also activate
latent TGF in transgenic cultures. The link between expres-
sion of a kinase-deficient type II TGF receptor and increased
TGF bioactivity appears, therefore, to include increased ex-
pression of TGF1 as well as greater activation of latent TGF
complex, which at least partly appears MMP dependent.
The TRIIk-fib Transgene Is TGF- Regulated—We hy-
pothesized that expression of the TRIIk-fib transgene was
also regulated by TGF and suspected that low level expression
of the kinase-deficient type II receptor may facilitate basal
TGF signaling via endogenous receptors, whereas higher ex-
pression levels were likely to be inhibitory. This was confirmed
in a series of cotransfection experiments using wild type fibro-
blasts harboring TGF responsive reporter constructs and dif-
ferent amounts of pCMV-TRIIk. At low levels there was
increased expression of a TGF-regulated reporter, while
higher pCMV-TRIIk concentrations of reporter gene expres-
sion returned to basal, or was suppressed. Data shown for a
3TP-luciferease reporter (Fig. 7) are summarized in three ex-
periments using replicate wells of wild type neonatal dermal
fibroblasts and are representative of the results of a series of
FIG. 5. Transgenic (tg) fibroblasts demonstrate enhanced re-
modeling and contraction of fibroblast-populated collagen lat-
tices. A, transgenic fibroblasts show enhanced contraction of fixed
FPCL over 24 h compared with littermate wild type (wt) fibroblasts
seeded at equivalent density. B, there is also increased contraction of
free-floating FPCL after 16 h. C, contraction of free-floating FPCL
induced by TGF1 in wild type cultures is blocked by GM6001, con-
firming dependence upon MMP activity. Conversely, GM6001 does not
inhibit the enhanced gel contraction shown by transgenic fibroblasts,
suggesting that other mechanisms are also important. Data summarize
a series of three independent experiments.
FIG. 6. TGF expression and bioactivity is increased in
transgenic mice. A, transgenic fibroblasts produce and activate
TGF more than wild type cells, assessed using a TGF bioassay
using mink lung epithelial cells stably transfected with a PAI-1-
luciferse reporter construct. B, increased expression of TGF iso-
forms in transgenic mouse skin stained using a monoclonal antibody
specific for active TGF isoforms (1D11). C, an MMP inhibitor
(GM6001) reduces the level of active TGF in transgenic fibroblast
culture supernatant but does not affect total TGF bioactivity. Data
summarize three independent experiments.
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parallel studies (n  3) using PAI-1-Luc or Col1a2-Luc. Co-
transfection of a non-TGF-regulated reporter construct was
used to correct for transfection efficiency in these studies.
Earlier experiments performed in the type I tight skin mouse
suggested that fibroblast-specific reporter gene expression
might be up-regulated by TGF (23). This was confirmed in the
present study using dermal fibroblasts cultured from TRIIk-
fib mice. Thus, levels of co-expressed -galactosidase were sig-
nificantly increased by recombinant TGF1, with maximum
induction at 24 h. There was a subsequent fall in reporter gene
expression back to basal expression levels at 48- and 72-h time
points, consistent with our observation for other TGF-regu-
lated transcripts including TIMP1 and MMP-9 (Fig. 4B). In-
duction at 24 h was maximal for fibroblasts cultured from
10-day-old mice but remained significant up to 6 weeks (Fig.
8A). To determine whether the constitutive level of transgene
expression was regulated by TGF in vivo, a series of neutral-
ization experiments were undertaken using the pan-isoform-
specific anti-TGF antibody 1D11. This antibody, but not an
isotype-matched control antibody of irrelevant specificity, re-
duced in vivo transgene expression by 	50% (Fig. 8B). Thus,
for transgenic mice injected with the irrelevant 13C4 mono-
clonal there was an increase in expression of the transgene
between genotyping biopsy performed at the 6-day and analy-
sis at a 10-day time point. In contrast, mice injected with 1D11
expressed transgene at only around half the level of the 13C4-
injected pups at 10 days. These results provide strong support
for regulation of TRIIk transgene expression by endogenous
TGF in vivo and suggest that anti-TGF treatment may be an
effective way of abrogating the mouse phenotype. Our previous
work (23) identified the fibroblast-specific enhancer as a target
for activation by TGF1. To circumvent potentially confound-
ing effects of TRIIk coexpression we investigated TGF reg-
ulation of the fibroblast-specific expression cassette in fibro-
blasts cultured from 6-kb LacZ reporter mice in which the 6-kb
fibroblast-specific enhancer was linked to a minimal endoge-
nous promoter driving a LacZ reporter gene (described in detail
in Ref. 23). To delineate the downstream pathways that are
important in activating the transgene we used inhibitors of
potential downstream pathways that have been implicated in
mediating transcriptional activation of Col1a2, including Sp1,
AP-1, and Smad signaling (36, 37). Thus transfection of an
expression vector encoding Smad7 was used to inhibit Smad-
dependent signaling, mithramycin as an antagonist for Sp1,
and curcumin to inhibit AP-1 signaling. Through this ap-
proach, we confirmed that TGF1 up-regulated the fibroblast-
specific expression cassette and that this depended upon Sp1,
and to a lesser degree, Smad activity, but was independent of
AP-1 (Fig. 8C). A construct in which the 6-kb upstream en-
hancer fragment region was linked to a minimal thymidine
kinase promoter was used in transient transfection to confirm
that the TGF responsive elements are likely to be within the
upstream fibroblast-specific enhancer element (Fig. 8D), al-
though it is likely that TGF responsive elements within the
proximal Col1a2 promoter may also be involved.
Collectively, our results demonstrate activation of the TGF
axis at multiple levels in transgenic mice expressing TRIIk
selectively on fibroblasts. Fibroblast gene and protein expres-
sion in the transgenic mice shares many hallmark features of
chronic fibrosis. Because TRIIk functions as a dominant
negative inhibitor of TGF signaling at high expression levels,
and the fibroblast-specific expression cassette is also partially
regulated by TGF, basal differences in gene expression are
normalized or reversed by recombinant TGF1 for a subset of
genes in vitro. In vivo, this mechanism may underlie balanced
activation of TGF signaling in the TRIIk-fib strain and is
likely to protect mice from the deleterious consequences of
uncontrolled TGF overactivity in growth and development.
DISCUSSION
A large body of indirect evidence supports a role for increased
TGF bioactivity in the pathogenesis of fibrosis. To obtain more
direct evidence we have used fibroblast-directed transgenesis
to assess the potential contribution of altered TGF signaling
in fibroblasts. This experimental strategy allows altered TGF
signaling in fibroblasts to be examined while minimizing ef-
fects in other cell types. The present study extends our analysis
of a novel genetically determined mouse model of fibrosis, the
TRIIk-fib strain. In our initial description we reported that
a kinase-deficient human type II TGF receptor leads to fibro-
sis in transgenic mice (21). This surprising finding raised ad-
ditional questions concerning the role of secondary signaling
mediators in determining the biochemical phenotype, and the
mechanism by which a kinase-deficient type II TGF receptor
might activate downstream signaling pathways. In the present
study we have analyzed altered gene expression in TRIIk-fib
transgenic fibroblasts and confirmed the pivotal role of endog-
enous TRI receptor kinase (ALK5). We also show that the
TRIIk-fib transgene is itself regulated by TGF. Interest-
ingly, the transgene facilitates TGF signaling via ALK5 at low
expression levels but is inhibitory at higher levels, thereby
establishing balanced up-regulation of TGF signaling in
transgenic fibroblasts. Together our data reaffirm the impor-
tance of TGF activation in fibrosis and demonstrate that
perturbation of receptor expression may result in multilevel
activation of the TGF ligand-receptor axis.
Initial biochemical characterization of the TRIIk-fib
mouse strain suggested increased activation of intracellular
signaling pathways downstream of TGF. The present study
confirms perturbation of Smad-dependent signaling with al-
tered expression and localization of phosphorylated Smad2/3 in
transgenic compared with wild type littermate fibroblast cul-
tures. Global gene expression profiling defines a cohort of dys-
regulated genes in this mouse strain and confirms that dermal
fibroblasts have a TGF-activated phenotype, and share many
hallmark features seen in chronic fibrosis. Similar approaches
have been applied to whole tissue or explanted cell cultures
from human fibrotic diseases including SSc and pulmonary
fibrosis (38) and a number of animal models of fibrosis (16).
While recognizing that -fold-change in mRNA may not neces-
FIG. 7. Low level expression of TRIIk activates a TGF-
regulated promoter. Data show activation of the 3TP-Luc reporter
construct and are representative of a series of three experiments using
TGF-regulated constructs. Correction for transfection efficiency is
made using a cotransfected reporter construct driving LacZ, and results
are expressed as relative light units (RLU) Luc/LacZ. Equal total DNA
was transfected per well into subconfluent cultures of wild type
dermal fibroblasts.
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sarily correlate with biological importance, we chose to focus
initially upon the most dysregulated genes. A relatively strin-
gent cut off of at least 2.5-fold up- or down-regulation was
selected. -Fold differences at this level were invariably deter-
mined as significant (p  0.001) by the MAS5.0 analysis soft-
ware. Our findings provide robust confirmation that TRIIk-
fib transgenic fibroblasts in culture show a TGF-activated
phenotype with the most highly overexpressed genes being
PAI-1 and CTGF. Gene expression profiles provide a large
volume of data but there are well recognized limitations to
interpretation. First, there are technical considerations be-
cause some oligonucleotide sets used on the Affymetrix gene-
chip may have poor discriminatory potential (39). This may
explain the disparity between the gene array results and those
obtained from other methods including quantitative real-time
RT-PCR and immunolocalization of protein using Western blot
or immunostaining of cultured cells. In addition, only two pairs
of fibroblast strains were examined by genechip analysis,
whereas for PCR and protein analysis far more samples were
evaluated. There was some variability in results between ex-
periments although trends of differential expression were con-
sistent. There is disparity between protein and mRNA data for
a number of gene products. For example, basal expression of
pro-2(I) collagen is 	10-fold greater in transgenic than wild
type fibroblasts, whereas mRNA expression levels were only
2-fold greater by Northern blot analysis. Although this extends
our earlier observation of high levels of type I collagen protein
secretion by this transgenic strain, it suggests that this is not
solely dependent upon increased mRNA or indeed transcrip-
tional activation. Confirmation that CTGF mRNA was highly
overexpressed supports previous results showing protein up-
regulation (21). The significance of this is unclear, although a
body of evidence suggests that CTGF, especially in combination
with TGF, is fibrogenic (2). It may be, however, that CTGF is
FIG. 8. Fibroblast-specific transgene expression is regulated by TGF1. A, recombinant TGF1 (4 ng/ml for 16 h) stimulated transgene
expression (coexpressed LacZ) in TRIIk-fib fibroblasts explanted from the skin of mice aged 3 days, 10 days, or 6 weeks. B, in vivo administration
of a pan-specific TGF neutralizing antibody reduces transgene expression in neonatal fibroblasts. Data summarize a series of independent
experiments comparing the expression of LacZ at 6 and 10 days after treatment with anti-TGF1 (1D11) or an isotype-matched control antibody
(13C4). Expression increased between 6 and 10 days in control mice but was substantially reduced in mice treated with 1D11. C, transgenic
fibroblasts cultured from 6-kb LacZ reporter transgenic mice show TGF responsiveness of the reporter transgene that is Sp1- and Smad-de-
pendent because mithramycin or cotransfected pCMV-Smad7, but not curcumin, attenuated LacZ induction. D, the 6-kb far-upstream enhancer
linked to a thymidine kinase promoter driving LacZ is also TGF responsive, confirming that elements within the upstream promoter are
responsive to TGF1. Expression is adjusted relative to a control plasmid (see text). Expression in panels A–C is corrected for lysate DNA
concentration as a surrogate for cell number. Data summarize three independent experiments.
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a marker rather than mediator of the fibrotic phenotype. There
is considerable evidence that CTGF is elevated in a large num-
ber of fibrotic diseases including SSc (1). It is interesting that in
this transgenic model CTGF overproduction appears to require
continued activation of the TRI kinase, contrasting with re-
ports suggesting that in SSc up-regulation of CTGF may be
TGF independent (28, 38, 40).
The TRIIk-fib mouse strain provides a valuable tool for
elucidating the regulation of metalloproteinase gene expres-
sion by TGF. Our quantitative RT-PCR results suggest that a
subset of MMPs and TIMPs are abnormally expressed by
TRIIk-fib transgenic fibroblasts, whereas the same cohort of
MMP genes is up-regulated by TGF in control strains. Al-
though MMPs are critical for connective tissue breakdown and
remodeling they are also important regulators of cytokine bio-
activity and receptor expression. Thus, it is possible that MMP
overexpression, including MMP3 and MMP9, both of which
activate latent TGF complex, could contribute to fibrogenesis.
Consistent with this the broad spectrum MMP inhibitor
GM6001 reduced levels of active TGF in transgenic fibroblast
culture supernatants. Previous reports have suggested that
MMP-dependent TGF activation is important in regulating
osteoblast differentiation (29) and our results suggest that
similar mechanisms may pertain to fibroblasts.
In earlier work we showed that a number of basally up-
regulated genes in TRIIk-fib fibroblasts were suppressed
24 h after stimulation with recombinant TGF1 (21). Here,
analysis of the time course for induction of MMP genes in
transgenic fibroblasts shows that for some transcripts a tran-
sient increase in mRNA is followed by suppression. This down-
regulation of TGF responsive genes suggests a TGF-induci-
ble suppressor mechanism. A number of endogenous inhibitors
may be relevant but the transgene product is also a very plau-
sible candidate. Importantly, although transgene expression
returns to its basal level in fibroblasts after initial induction by
recombinant TGF1, similar to transcripts such as TIMP1 or
PAI-1 (21), expression is not abolished completely, unlike other
transcripts such as MMP-13 (Fig. 4B). This suggests that al-
though TGF1-dependent transcriptional activators can mod-
ulate activity of the fibroblast-specific transgenic promoter
other, presumably lineage-specific, transactivating factors de-
termine constitutive activity. If transgene expression were
abolished this might have abrogated the in vivo phenotype of
the TRIIk-fib strain.
Experiments using SD-208 strongly suggest that activation
of the type I TGF receptor ALK5 is a key determinant of the
profibrotic phenotype in the TRIIk-fib transgenic mouse
strain. Moreover, examination of endogenous receptor levels in
transgenic fibroblasts suggest that levels of wild type TRII are
substantially increased compared with littermate wild type
strains. This provides a plausible mechanism whereby basal
signaling is activated. Our data suggest that low levels of
TRIIk expression facilitate basal TGF signaling, whereas
higher levels of expression are inhibitory. We confirm in vitro
that the fibroblast-specific expression cassette is up-regulated
by TGF in fibroblast cultured from transgenic mice and ex-
tend earlier work by showing that up-regulation involves both
Smad-dependent signaling and also Sp1, but not AP-1 activity.
Our in vivo studies show that a pan-isoform specific anti-TGF
monoclonal reduced expression of a fibroblast-specific reporter
gene. Together, our results elucidate the mechanism underly-
ing balanced up-regulation of TGF signaling pathways in the
TRIIk transgenic mouse strain and provide insight as to how
altered TGF signaling can sustain a fibrotic phenotype. Thus,
expression of the transgenic receptor on fibroblasts at levels
similar to that of the endogenous type II receptor activates
TGF signaling, probably by facilitating activation of the TRI
kinase. The molecular mechanism by which co-expression of a
kinase-deficient type II TGF receptor on fibroblasts activates
signaling is uncertain. Gene expression profiling studies did
not identify significant differences between transgenic or wild
type levels of mRNA encoding TRI or TRII and so increased
biosynthesis seems unlikely. Another possibility is that at low
transgene expression levels heterodimers form with wild type
TRII and that the resulting complexes signal more efficiently,
have greater ligand affinity, or are internalized and degraded
more slowly than those homodimeric receptor complexes. The
latter would be consistent with increased TRII levels in trans-
genic fibroblast lysates. Interactions between pathway-specific
ubiquitin ligases and heterodimeric receptor complexes are
likely to be different from wild type receptor homodimers (41).
Recent reports suggest that the ratio of type I (TRI) to type II
(TRII) receptors may determine basal activity of the TGF
signaling pathway (42) and the mutant receptor may increase
the ratio of TRI:TRII in transgenic fibroblasts. At higher
FIG. 9. Schematic summarizing multilevel activation of the
TGF ligand-receptor axis in TRIIk-fib transgenic mice. A,
expression of the kinase-deficient type II TGF receptor at low levels
facilitates activation of the endogenous type I TGF receptor, at least in
part by increasing levels of wild type TRII. Downstream consequences
include up-regulation of TGF1 and other gene products that promote
TGF activity or activate the latent TGF complex. This results in net
activation of TGF signaling. B, in response to recombinant TGF1
there is significant elevation of transgene expression. Higher level
transgene expression is inhibitory and blocks signaling. Thus for tran-
scripts up-regulated at early time points by TGF1, such as TIMP1,
there is transient response in transgenic cells, but for transcripts in-
duced 12 h (such as MMP-3 and MMP-13) when the transgene is also
up-regulated, suppression is observed (see Fig. 3B). High level trans-
gene expression does not suppress the fibroblast-specific promoter com-
pletely suggesting that other TGF-independent pathways also govern
activity of this lineage-specific construct.
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concentrations homodimers of mutant receptor are likely to
form and these may inhibit responsiveness by direct competi-
tion for ligand with wild type receptors. A schematic summa-
rizing the potentially contrasting effect of different levels of
transgene expression is shown in Fig. 9.
There is a growing body of evidence suggesting that myofi-
broblasts are key players in the development of fibrosis (43).
For example, in SSc there are increased numbers of myofibro-
blasts in skin and lung tissue (5). Differentiation of a myofi-
broblast subpopulation of cells may be a critical regulatory step
in wound repair as well as pathological fibrosis. The present
study suggests that myofibroblasts are important in determin-
ing the phenotype of the TRIIk-fib strain. Moreover this
appears to be dependent upon TRI kinase activity because it
is blocked by the inhibitor SD-208. The functional conse-
quences of this are demonstrated by enhanced contraction of
tethered FPCLs by transgenic fibroblasts. It is noteworthy that
free floating collagen gel contraction by transgenic fibroblasts
was not significantly reduced by MMP inhibition in contrast to
wild type fibroblasts. This is surprising and suggests that other
cell properties, independent of MMP overexpression, are also
important.
Animal models provide a platform for evaluation of novel
antifibrotic therapies and there is considerable interest in tar-
geting TGF as a therapy for fibrosis. One strategy is to use
soluble antagonists of TGF. Many studies have shown that
anti-cytokine antibodies, soluble receptor fusion proteins, and
factors that bind active TGF ligand such as LAP or decorin
may have antifibrotic potential in animal models (1). There
have been recent trials of anti-TGFmonoclonal antibody ther-
apy for human fibrosis including a study of anti-TGF1 in early
stage systemic sclerosis (45). However, it has been suggested
that a key abnormality in SSc may not be overproduction of
TGF ligand but a more subtle disruption of signaling or re-
ceptor expression. Our findings support using ligand-directed
blocking strategies to treat fibrosis; however, this is likely only
to be truly effective if, as in the TRIIk-fib strain the primary
determinant of the phenotype is itself regulated by TGF.
Another potential approach is the use of small molecule inhib-
itors of downstream components of the TGF signaling cas-
cade. A number of ALK5 inhibitors have been tested in vitro,
although the advantage of specific versus broader spectrum
inhibition of this family of receptor kinases remains to be
determined (46). The present study confirms the potential for
ALK5 inhibition using one of these antagonists, SD-208, to
block key pathogenic mechanisms including collagen overpro-
duction, CTGF expression, and myofibroblast differentiation.
However, there have been few studies of such inhibitors in vivo
and formal comparison with other TGF blocking strategies
would be worthwhile. It is possible that only some of the impor-
tant biological effects of TGF are mediated via ALK5 (47). For
example, other BMP superfamily members may also be impor-
tant and it has recently been suggested that Alk1 and ALK5
stimulation by TGF ligand may have antagonistic effects (44).
In summary, we have explored the biochemical phenotype of
fibroblasts cultured from a novel transgenic mouse strain and
confirm that key features of human SSc are reproduced. We
show that fibroblast-specific TRIIk expression can stimulate
profibrotic pathways in a TGF-dependent manner, and eluci-
date the basis for balanced activation of TGF-regulated genes
by demonstrating that the transgene promoter is regulated by
TGF1, and that high level transgene expression antagonizes
the stimulatory effect of lower level expression.
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